
NRSN Stock Forecast & Price Target
NRSN Analyst Ratings
Bulls say
NeuroSense Therapeutics is in a favorable financial position with promising potential for its lead product candidate, PrimeC, in treating neurodegenerative diseases. Its promising results in pre-clinical and clinical studies for ALS, AD, and PD suggest a strong potential for future success, with a focus on targeting RNA regulatory pathways and utilizing a combination of FDA-approved drugs. However, financial constraints from its parent company, NeuroSense, could hinder the progress of PrimeC and more resources and funding are needed to advance the clinical trials and potentially bring PrimeC to market.
Bears say
NeuroSense Therapeutics is facing significant challenges in the development of its potential treatment for Alzheimer's disease and ALS. With an expected increase in the prevalence of these debilitating neurodegenerative diseases and a significant global healthcare burden, there is a high demand for effective treatments. However, the company may struggle with funding and regulatory hurdles, hindering its ability to bring PrimeC to market. As a financial analyst, this is a concerning outlook for the company's stock and its potential for future growth.
This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares